Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 14 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2016Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: results from an Australian early arthritis cohortWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2012Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritisWiese, M.; Schnabl, M.; O'Doherty, C.; Spargo, L.; Sorich, M.; Cleland, L.; Proudman, S.
2017Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritisWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; Mcwilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2015Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three yearsWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2011Decline in hand bone mineral density indicates increased risk for erosive change in early rheumatoid arthritis (RA)Black, R.; Spargo, L.; Schultz, C.; Chatterton, B.; James, M.; Cleland, L.; Hill, C.; Proudman, S.; Australian Rheumatology Association in conjunction with Rheumatology Health Professionals Association 52nd Annual Scientific Meeting (14 May 2011 - 17 May 2011 : Brisbane, Qld.)
2012Decline in hand bone mineral density indicates increased risk for erosive change in early rheumatoid arthritis (RA)Black, R.; Spargo, L.; Shultz, C.; Chatteron, B.; James, M.; Cleland, L.; Lester, S.; Hill, C.; Proudman, S.; RACP Future Directions in Health Congress 2012 (06 May 2012 - 09 May 2012 : Brisbane, Qld.)
2012Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low doseProudman, S.; Spargo, L.; Hall, C.; McWilliams, L.; Lee, A.; Rischmueller, M.; Gibson, R.; James, M.; Cleland, L.; Australian Rheumatology Association Annual Scientific Meeting (2012 : Canberra, A.C.T.)
2016Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Wabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Hall, C.; Spargo, L.; Metcalf, R.; Proudman, S.; Wiese, M.
2015Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritisProudman, S.; Cleland, L.; Metcalf, R.; Sullivan, T.; Spargo, L.; James, M.
2012Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritisO'Doherty, C.; Schnabl, M.; Spargo, L.; Cleland, L.; James, M.; Proudman, S.; Wiese, M.